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Abstract
Background Medications targeting stroke risk factors have
shown good efficacy, yet adherence is suboptimal. To im-
prove adherence, its determinants must be understood. To
date, no systematic review has mapped identified determi-
nants into the Theoretical Domains Framework (TDF) in
order to establish a more complete understanding of med-
ication adherence.
Purpose The aim of this study was to identify psychological
determinants that most influence stroke survivors’medication
adherence.
Methods In line with the prospectively registered protocol
(PROSPERO CRD42015016222), five electronic databases
were searched (1953–2015). Hand searches of included full text
references were undertaken. Two reviewers conducted screen-
ing, data extraction and quality assessment. Determinants were
mapped into the TDF.
Results Of 32,825 articles, 12 fulfilled selection criteria
(N = 43,984 stroke survivors). Tested determinants mapped
into 8/14 TDF domains. Studies were too heterogeneous for
meta-analysis. Three TDF domains appeared most influential.
Negative emotions (‘Emotions’ domain) such as anxiety and
concerns about medications (‘Beliefs about Consequences’
domain) were associated with reduced adherence. Increased
adherence was associated with better knowledge of medica-
tions (‘Knowledge’ domain) and stronger beliefs about med-
ication necessity (‘Beliefs about Consequences’ domain).
Study quality varied, often lacking information on sample size
calculations.
Conclusions This review provides foundations for evidence-
based intervention design by establishing psychological deter-
minants most influential in stroke survivors’ medication ad-
herence. Six TDF domains do not appear to have been tested,
possibly representing gaps in research design. Future research
should standardise and clearly report determinant and medi-
cation adherence measurement to facilitate meta-analysis. The
range of determinants explored should be broadened to enable
more complete understanding of stroke survivors’ medication
adherence.
Keywords Systematic review . Stroke .Medication
adherence . Psychological determinants
Introduction
Stroke is the second leading cause of death in developed coun-
tries [1] and can lead to life-altering consequences [2].
Guidelines recommend the use of medication for secondary
prevention of stroke [3–5]. These medications target stroke
risk factors such as high blood pressure and high serum cho-
lesterol values. The medications prescribed for stroke risk fac-
tor control have shown good efficacy in the literature and
reductions in the rate of stroke recurrence per annum [6, 7],
with cumulative reductions in relative risk by as much as 75%
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[8]. Nonetheless, adherence rates to stroke prevention medi-
cations remain suboptimal [e.g. 9, 10].
For the purpose of this review, medication adherence is
defined as “the extent to which the patient's action matches
the agreed recommendations” [10]. Among individuals with
long-term conditions, 33–50% of patients were non-adherent
to long-term medications [10]. Among stroke survivors, a re-
cent systematic review reported a pooled prevalent non-
adherence rate of 30.9% (95% CI 26.8–35.3%) [11]. A better
understanding of the underlying reasons for suboptimal adher-
ence will enable more informed intervention development.
Therefore, the aim of this systematic review was to identify
psychological determinants that influence medication adher-
ence in stroke survivors.
Current evidence has considered the role of psychological,
demographic, system, biological and other factors when trying
to understand medication adherence. Determinants, such as be-
liefs about medication, presence of other comorbid conditions,
age and lack of clinical symptoms have been previously identi-
fied as influential in stroke survivors’ medication adherence
[12–15]. The negative consequences of taking medications, in-
cluding unpleasant side effects and drug interactions, as well as
difficulty accessing the prescribing clinician or pharmacy and
issues with prescription costs, could also contribute to non-
adherence [e.g. 11, 16–18]. Moreover, current interventions
have had limited success at effectively improving medication
adherence [e.g. 19]. Some determinants of medication adher-
ence, such as age, gender or stroke type [11], are not easily
modified. Therefore, a better understanding of the modifiable
determinants of medication adherence is required to facilitate
the design of behaviour change interventions. Psychological
determinants, defined as determinants of, or relating to, themind
or mental processes, also relating to or affecting a person’s emo-
tional state [20], are one type of potentially modifiable determi-
nant. Considerable research effort has been made to link psy-
chological determinants to the behaviour change techniques
(BCTs) likely to change each one [21, 22]. This could facilitate
adherence intervention design. Consequently, the current review
focused on identifying the strongest psychological determinants
of medication adherence in stroke survivors and considered the
quality of the primary studies.
Many theories of the psychological influences on behav-
iour have been developed (e.g. Theory of Planned Behaviour
[23] and Health Belief Model [24, 25]). However, such theo-
ries of health behaviour have been subject to a number of
criticisms, including not always operationalising the con-
structs clearly, not considering the context in which a behav-
iour occurs and an over emphasis on rational, deliberative
determinants. As there is considerable unexplained variance
in adherence, the addition of further predictor variables should
enhance the theories (see [26]). In partial response to the latter
two criticisms, the Theoretical Domains Framework (TDF)
has been developed [27, 28].
The TDFwas developed via an expert consensus approach.
Behaviour change professionals identified constructs from
many major behaviour change theories. The identified con-
structs were clustered using open and closed sort tasks, group-
ing similar constructs together to form, what the authors
termed, a domain. After revisions, 14 key domains were
established (Knowledge; Skills; Social/Professional role and
identity; Beliefs about capabilities; Optimism; Beliefs about
consequences; Reinforcement; Intentions; Goals; Memory,
Attention and Decision processes; Environmental context
and resources; Social influences; Emotions; and Behavioural
regulation [28]). The TDF provides more comprehensive cov-
erage of influences on behaviour than any single theory of
behaviour and was therefore used as a theoretical framework
in this review. A further advantage of the TDF is that the
domains can be mapped to BCTs that are thought to be most
likely to change each type of determinant [28, 29].
The aim of this systematic review was to identify psycho-
logical determinants that influence medication adherence in
stroke survivors. The secondary aim was to establish the mag-
nitude of the relationships between the psychological determi-
nants and stroke survivors’ medication adherence. To our
knowledge, there has not yet been a review, which has
mapped identified determinants into the TDF in order to es-
tablish a more complete understanding of medication adher-
ence in stroke survivors.
Methods
This review includes studies focused on people with a
clinical diagnosis of stroke (ischaemic or haemorrhagic)
and prescribed medications that targeted stroke risk fac-
tors for secondary prevention. The Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
(PRISMA) guidelines were followed [30]. The system-
atic review protocol was prospectively registered on
PROSPERO (CRD42015016222).
Search Strategy and Selection Process
The search targeted literature investigating psychological de-
terminants of medication adherence in stroke survivors. A
multi-method search was undertaken using combined terms
for stroke AND adherence AND psychological determinants
and a combination of subject heading and free text searching
where applicable (See Supplement 1 for tailored search
strategy). Sources included MEDLINE, EMBASE,
PsycINFO, CINAHL, Web of Science (inclusive of confer-
ence proceedings) and reference lists of included full text ar-
ticles. The search was limited to English language as this was
the only fluent language understood by the review team. The
inception date of the search was 1953 because literature
ann. behav. med.
regarding “compliance” in healthcare started to appear from
the early 1950s [31]. Eligibility and selection of relevant arti-
cles were assessed by first conducting title/abstract review and
then by assessing full texts according to predefined inclusion/
exclusion criteria. COVIDENCE software was used to man-
age this process. The selection process, data extraction and
quality assessment were performed independently by two re-
viewers (EC, MF). A third reviewer resolved conflicts and
cross-checked data extraction (AJW). Reviewer EC extracted
data from all included full texts. Reviewer MF extracted data
from a proportion (10%) of the full texts and extracted all
subjective and outcome data from the remaining texts
(90%). If reviewers required more information, the authors
were contacted. Seven of the 19 authors contacted responded.
Figure 1 displays the PRISMA diagram of the search and
selection process.
Criteria for Study Inclusion and Exclusion
Inclusion criteria:
& Studies with a sample of stroke survivors or mixed
transient ischaemic attack (TIA)/stroke survivors
who were ≥18 years of age and had been prescribed
medication(s) that targeted at least one stroke risk
factor
& Primary research studies with quantitative research de-
signs measuring at least one psychological determinant
and medication adherence
Exclusion criteria:
& Studies with a sample of stroke survivors <18 years of age
& Mixed condition samples where stroke only data could not
be obtained
& Reviews (systematic, narrative or meta-analytic), studies
applying retrospective data collection and qualitative
study designs
Randomised control trials (RCTs) were not explicitly
excluded from the search strategy, but only one RCT iden-
tified was relevant to the review research question [32].
The RCT had been informed and was a sequel to an
observational study identifying psychological determinants
[13]. Therefore, for this review, the inclusion of the ob-
servational study design was considered most appropriate.
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Fig. 1 PRISMA diagram
ann. behav. med.
Data Extraction and Analysis
Data Extraction
Data extraction was completed using a proforma developed
for this review, in accordance with Cochrane guidance [33].
The data extracted included: (1) participant clinical and demo-
graphic characteristics, (2) study design and methods, (3) ad-
herence measures, (4) identified psychological determinants
and (5) statistical information.
Analysis
Summary data from each full text were extracted. The analysis
within this review focused on the effect sizes of the relation-
ship between medication adherence/persistence and the deter-
minants given. Data collection methods from the included
papers were too heterogeneous to allow for a meta-analysis.
The determinants were grouped into the relevant TDF do-
mains. To identify which domains were most influential to
adherence, assessment of the domains with a higher number
of tested determinants with significant associations was car-
ried out. The number of papers and samples that a determinant
was tested in was also extracted and used to establish domains
with the most influence on medication adherence. Domains
were considered more influential when a larger proportion of
the tested determinants had significant associations with ad-
herence and where significant associations were found in a
higher proportion of the samples in which at least one deter-
minant from the domain was tested.
Quality Assessment
Quality assessment was conducted independently by two re-
viewers (EC, MF) using the 13-item checklist designed by
Walburn and colleagues [34] to appraise studies of attitudes
to medicines. The checklist assesses items such as a priori
aims, definition/size of population under investigation, sample
size calculations and justification that the sample is represen-
tative of population. The checklist is not intended to provide a
defined cutoff study quality score, belowwhich studies should
be excluded from analysis. Instead, using the checklist facili-
tated qualitative consideration of the impact of study design
features on findings.
Determinant Mapping
Two coders (EC and SJB), with qualifications in Health
Psychology (MSc, PhD and MSc), independently mapped
the identified psychological determinants into TDF domains.
Domain definitions were taken from the most recent version
of the TDF at the time of this review [28]. One coder (MA), a
qualified general practitioner with experience in mental health
research, resolved disputes. Determinants were coded
into the most suitable domain, or domains if it was
agreed that the determinant fitted into more than one,
or not coded if none of the domains seemed appropri-
ate. Where possible, the wording of the items used to
measure a determinant was checked to ensure domains
were coded in line with what was measured, rather than
simply the label given to a determinant by the study
authors. Cohen’s kappa for agreement between the two coders
[35] was k = 0.69 (SE = 0.07 [95% CI = 0.56–0.82]), indicat-
ing substantial agreement.
Results
A search from inception until November 2015 produced a
total of 32,845 articles (duplicates removed). Titles and ab-
stracts were screened, producing 90 full texts to assess.
Following assessment of full texts, 12 papers reporting on
seven samples met inclusion criteria (Fig. 1).
Study Characteristics
Detailed study characteristics can be found in Table 1. The 12
papers were derived from seven samples, with another two of
the papers posing a potential for overlap. Therefore, results
will now be considered by displaying the number of papers
(x/12) and number of samples (x/7), relevant to each factor.
Most studies (9/12, 5/7) assessedmedication adherence. Three
of the twelve studies (2/7 samples) assessed medication per-
sistence [40, 43, 44]. The total sample size was 43,984 (range
25 to 21,077). Research was conducted in four countries
(USA, Australia, Sweden and UK) across three continents.
Settings for participant recruitment included hospital (5/12,
4/7) [39–41, 43, 44], community (6/12, 2/7) [36–38, 42, 45,
46] and an outpatient setting (1/12, 1/7) [13]. The reported
stroke subtypes included ischaemic (6/12, 5/7) [13, 39–41,
43, 44], haemorrhagic (3/12, 3/7) [39, 40, 42] and TIA
(6/12, 2/7) [37, 38, 43–46], with the majority of papers
reporting samples with mixed subtypes (75%). In seven pa-
pers (3/7 samples), the stroke subtype was either undefined or
only some of the sample’s stroke subtypes were defined.
Time periods between measurement of determinants and
adherence varied, with 6/12 papers, 2/7 samples using cross-
sectional designs [36–38, 41, 45, 46] and follow-up time
frames for prospective studies of 5–6 weeks (1/12, 1/7) [13],
3 months (2/12, 2/7) [42, 43], 12 months (2/12, 2/7) [39, 44]
and 24months (1/12, 1/7) [40]. A range of questionnaire items
(validated and non-validated) was used tomeasure psycholog-
ical determinants. Some papers did not clearly describe how
determinants were measured.
ann. behav. med.
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Measurement of Adherence
Avariety of methods were used to measure medication adher-
ence (Supplement 2). These included the use of self-report
measures such as the Medication Adherence Report Scale
(MARS) and more objective methods such as conducting pill
counts and monitoring prescription refills. In total, seven dif-
ferent methods were applied (3 subjective, 4 objective), either
alone or in conjunction with another. Six articles (50%, 5/7
samples) named the specific medications being assessed for
adherence. Of these, five considered antiplatelet, anti-hyper-
tensive, cholesterol-lowering and anti-coagulant medications
[39–41, 43, 44] and one assessed adherence to antiplatelet,
anti-hypertensive and cholesterol-lowering medications [13].
Quality Assessment
Study quality was varied (Supplement 3). Checklist scores
ranged from 8 to 10 (mean = 9.3) out of a possible 13. All
included studies reported explicit a priori aims, a sample def-
inition and size, inclusion/exclusion criteria, a response/
dropout rate where applicable and whether the research was
independent of routine practice. However, only two studies
gave a sample size calculation [13, 42]. In addition, although
seven studies stated the response/dropout rate [13, 39–44],
which ranged from 56 to 96%, only two provided justification
for these rates [13, 39]. There was no clear justification of
sample representativeness in four studies [13, 39, 43, 44]. In
addition, the majority of included studies had designed ques-
tionnaires or interview schedules purposely for the research
derived from validated and non-validated measures. Three
studies did not make the original questionnaire available or
provide sufficient information on how all determinants were
measured [13, 43, 44], and four studies did not justify the
reliability/validity of the measures used [40, 41, 43, 44].
Determinant Mapping
There were 48 distinct determinants measured across the 12
papers, reporting on seven samples. The most common deter-
minants (6/12 papers, 4/7 samples) were variations of con-
cerns about medications and beliefs about necessity of
medications. Five of 12 articles (4/7 samples) also assessed
depression as a determinant of medication adherence. Over
half the tested determinants were only measured in one study.
Table 2 displays the identified determinants from the review
mapped into TDF domains. Determinants tested in the papers
could be mapped into 8/14 domains. There were no tested
determinants that mapped into ‘Social/Professional role and
identi ty’ , ‘Optimism’ , ‘Reinforcement’ , ‘Goals’ ,
‘Environmental context and resources’ and ‘Behavioural reg-
ulation’. One tested determinant, quality of life (as measured
by increments of 10% in EuroQoL-5D score) could not beTa
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mapped into the TDF, as no definition seemed appropriate.
Only four determinants (patient reported and partner reported
inertia, patient helplessness and affective illness items) were
considered to fit within two separate TDF domains (see
Table 2 for determinant mapping). All other determinants sat
discretely within one domain. A total of 33 distinct determi-
nants, corresponding to seven TDF domains, significantly in-
fluenced adherence/persistence behaviour (Table 3). Each do-
main will now be discussed in turn (for numerical details of
observed associations and p values, see Table 1).
‘Knowledge’
Seven distinct determinants mapped into this domain. Two
determinants did not have a significant effect on adherence
Table 2 Determinants mapped into the theoretical domains framework
Domain Descriptiona Determinant
Knowledge An awareness of the existence of
something
Receiving medication
instructions
Understanding why
medications are being
taken
Understanding medication
side effects
Low knowledge of stroke
risk factors
Understanding how to
refill meds
Self-perceived general
health
Self-reported bad general
health
Skills An ability or proficiency
acquired through practice
Planning and organisation
Language skills
Social/Professional
role and identity
A coherent set of behaviours
and displayed personal
qualities of an individual in a
social or work setting
Beliefs about
capabilities
Acceptance of the truth, reality,
or validity about an ability,
talent, or facility that a
person can put to
constructive use
Cognitive illness items
Helplessness
Optimism The confidence that things will
happen for the best or that
desired goals will be attained
Beliefs about
consequences
Acceptance of the truth, reality,
or validity about outcomes of
a behaviour in a given
situation
Concerns about
medications
Affective illness items
Beliefs about necessity
Perceived benefit of
medication
Cognitive treatment items
Affective treatment items
Risk perception of risk of
further stroke
Beliefs about benefit
Beliefs about overuse
Beliefs about harm
Illness
perceptions-acute/-
chronic timeline
Illness
perceptions-treatment
control
Reinforcement Increasing the probability of a
response by arranging a
dependent relationship, or
contingency, between the
response and a given
stimulus
Intentions A conscious decision to perform
a behaviour or a resolve to
act in a certain way
Desire for medication now
Goals Mental representations of
outcomes or end states that
an individual wants to
achieve
Memory, Attention
and Decision
processes
The ability to retain
information, focus selectively
on aspects of the environment
and choose between two or
more alternatives
MMSE score
RMBT score
Patient memory
Environmental
context and
resources
Any circumstance of a person’s
situation or environment that
discourages or encourages
Table 2 (continued)
Domain Descriptiona Determinant
the development of skills and
abilities, independence,
social competence, and
adaptive behaviour
Social influences Those interpersonal processes
that can cause individuals to
change their thoughts,
feelings, or behaviours
Support of next of kin
Low trust in personal
doctor
Perceived discrimination
on account of race,
ethnicity, education or
income
Dissatisfied with care
Dissatisfied with support
Satisfaction with hospital
care/support
Care received at home
Inertia
Inertia (rated by partner)
Emotions A complex reaction pattern,
involving experiential,
behavioural, and
physiological elements, by
which the individual attempts
to deal with a personally
significant matter or event
Emotional dyscontrol
(rated by partner)
Emotional dyscontrol
Anger
PTSD symptoms
(Self-reported)
Depression/depressive
symptoms
Low mood
Fatigue
Indifference
Euphoria
Inertia
Inertia (rated by partner)
HADS total
Anxiety
Helplessness
Affective Illness Items
Behavioural
regulation
Anything aimed at managing or
changing objectively
observed or measured
actions
PTSD post-traumatic stress disorder, HADS The Hospital Anxiety and
Depression Scale, MMSE The Mini-Mental State Examination, RMBT
The Rivermead Behavioural Memory Test
a Definitions as stated in Cane et al. 2012who utilised the definitions from
the American Psychological Associations’ Dictionary of Psychology
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(self-reported bad general health and low knowledge of stroke
risk factors). Five significantly influenced medication adher-
ence/persistence. Generally, greater knowledge was associated
with better adherence/persistence. Four significant determi-
nants (receiving medication instructions, understanding how
to refill medications, understanding why medications are being
taken and understanding medication side effects) were all relat-
ed to adherence in this manner. Self-perceived general health
also had a significant effect on adherence, with poorer self-
perceived general health associated with poorer medication
persistence.
‘Skills’
Two distinct determinants tested (patient language skills (re-
ported by a partner) and patient planning and organisation
skills) mapped to this domain. Both determinants had a sig-
nificant effect on adherence, with poorer skills associated with
worse adherence.
‘Beliefs about Capabilities’
Two distinct determinants were tested, both significantly
influencing medication adherence. Patient helplessness had
a negative impact on adherence. Rating oneself as more help-
less was related to poorer adherence. Cognitive illness items,
assessing patients’ perceived control over stroke risk factors,
had a positive impact, with positive responses indicating
higher perceived risk factor control related to better self-
reported adherence.
‘Beliefs about Consequences’
Twelve distinct determinants were mapped to this do-
main. Three tested determinants were not found to have
a significant effect on medication adherence (illness
perceptions relating to acute/chronic timelines of a con-
dition, illness perceptions referring to treatment control
and perceived risk of further stroke). Four determinants
had a significant positive influence on medication adher-
ence. Greater perceived necessity of medications was
related to increased adherence (in 2/5 papers). Greater
perceived benefit of medications (measured in two
ways) was related to increased adherence. Higher scores
on cognitive treatment items (derived from items from
the specific necessity subscale of the Beliefs about
Medications Questionnaire (BMQ) plus a question re-
garding how much patients thought their medications
could prevent stroke) were related to better self-
reported adherence.
Five determinants significantly negatively influenced ad-
herence. When patients had greater concerns about
medications, beliefs about medication overuse and beliefs
about harm from medication adherence was worse. In addi-
tion, worse adherence was related to affective treatment items,
concerning worries about medications and affective illness
items concerning worries about stroke.
‘Intentions’
One determinant (desire for medications now) was tested, but
not found to have a significant effect on adherence.
Table 3 Table showing the number of significant determinants (and their negative or positive influence on adherence) within each domain
Domain Total no. of
determinants
tested across
all papers
No. of
determinants
significantly
associated
with better
adherence
No. of
determinants
significantly
associated
with worse
adherence
No. (%) of
determinants
tested not
significantly
related to
adherence
No. of the 12
papers reporting a
test of at least one
determinant from
this domain
No. of the 7
samples in which
at least one
determinant from
this domain was
tested
No. (%) of samples in
which determinants were
tested and at least one had
a significant association
with adherence
Knowledge 7 4 1 2 (29%) 5 4 3 (75%)
Skills 2 0 2 0 (0%) 1 1 1 (100%)
Beliefs about
capabilities
2 1 1 0 (0%) 2 2 2 (100%)
Beliefs about
consequences
12 4 5 3 (25%) 7 4 4 (100%)
Intentions 1 0 0 1 (100%) 1 1 0 (0%)
Memory,
attention and
decision
processes
3 0 1 2 (67%) 2 2 1 (50%)
Social
influences
9 2 3 4 (44%) 4 4 3 (75%)
Emotions 15 0 13 2 (13%) 7 4 3 (75%)
ann. behav. med.
‘Memory, Attention and Decision Processes’
Three distinct determinants were tested of which two were not
significant (Mini Mental State Exam (MMSE) score and
Rivermead Memory Behavioural Test (RMBT) score). In con-
trast, Patient memory (measured by the Everyday Functioning
Questionnaire (EFQ)) significantly influenced medication ad-
herence. Poorer reported memory or memory deficits were
related to poorer adherence.
‘Social Influences’
Nine distinct determinants were tested and mapped into this
domain. Four (low trust in personal doctor, dissatisfaction
with care, dissatisfaction with support and satisfaction with
hospital care/support) did not have a significant effect on
medication adherence/persistence. Two determinants had a
significant positive influence on medication adherence/persis-
tence. Increased support from the next of kin was related to
better persistence with anti-hypertensive and warfarin medi-
cations. Moreover, higher levels of care received at home
were associated with better adherence. In contrast, three deter-
minants negatively influenced adherence. Greater perceived
discrimination due to race, ethnicity, education or income
increased odds of non-adherence. In addition, both pa-
tient-rated and partner-rated inertia influenced adherence
negatively. Increasing levels of inertia appeared to relate to
increased non-adherence.
‘Emotions’
Fifteen distinct determinants were tested. Two determinants
((self-reported) depression/depressive symptoms and
Hospital Anxiety and Depression Scale (HADS) total score)
were not significantly associated with medication adherence.
Thirteen determinants had a significant negative influence on
adherence/persistence. Adherence/persistence was poorer
when patients had greater patient-reported or partner-rated
emotional dyscontrol (measured via two different measures);
post-traumatic stress disorder (PTSD) symptoms; more
anger; greater patient-reported or partner-rated inertia; more
fatigue, euphoria, indifference, anxiety, low mood; and higher
perceived helplessness or scores on affective illness items
(concerning worries about stroke).
Discussion
The purpose of this review was to identify psychological de-
terminants that influence medication adherence in stroke sur-
vivors. Forty-eight distinct determinants were assessed in 12
articles representing seven samples. The identified determi-
nants were mapped into TDF domains, in order to develop a
theoretical understanding of how these determinants influence
medication adherence and to inform future work. Based on
this review, the ‘Emotions’ (at least one significant determi-
nant in 3/4 samples in which they were tested, 86% of tested
associations statistically significant), ‘Knowledge’ (at least
one significant determinant in 3/4 samples in which they were
tested, 79% of tested associations statistically significant) and
‘Beliefs about consequences’ domains (at least one significant
determinant in 4/4 samples in which they were tested, 75% of
associations statistically significant) appear to have the stron-
gest influence onmedication adherence. The TDF has enabled
a holistic approach to understanding medication adherence
that will be important in future intervention development.
Within the Emotions domain, emotional distress such as
‘anxiety’, ‘PTSD’ and ‘emotional dyscontrol’ was found to
have an influence on medication adherence. Similar findings
have emerged in recent literature, corroborating this finding.
For example, Gentil and colleagues (2012) assessed anti-
hypertensivemedication adherence in community-living older
adults, finding that adherence was lower when partici-
pants had an anxiety or depressive disorder [47]. In
addition, a large American study (n = 1342) found a
significant association between the presence of mental
health conditions (anxiety/depression) and difficulty tak-
ing anti-hypertensive medications [17].
Within the ‘Knowledge’ domain, understanding why med-
ications were being taken and understanding medication side
effectswere found to have influence on medication adherence.
Previous literature has found to be similar. A prospective co-
hort study interviewing 130 stroke survivors and 85 caregivers
found large gaps in stroke survivor and caregiver knowledge.
For example, 52% of patients were unable to name stroke risk
factors. This sample also demonstrated suboptimal health be-
haviours, with 28% of the patients reporting non-adherence
[48]. More recently, a qualitative study identifying barriers to
medication adherence with stroke survivors, caregivers and
general practitioners in the East of England found similar re-
sults [49]. Knowledge of stroke and medication was identified
as a patient-level barrier to adherence of secondary prevention
medication [49].
Within the ‘Beliefs about consequences’ domain, both con-
cerns about medication and beliefs about the necessity of
medication were the most common determinants with influ-
ence. This is commensurate with previous research. In a meta-
analytic review assessing the influence of necessity beliefs
and concerns on adherence in patients with long-term condi-
tions, higher adherence was related to increased beliefs about
necessity of treatment. Likewise, poorer adherence was asso-
ciated with increased concerns about treatment [50].
Moreover, recent research suggests interventions targeting
perceived necessity and concerns about medications increase
stroke survivors’ medication adherence [32, 51]. Therefore,
those beliefs appear to play a causal role in adherence.
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Quality of Included Studies
All 12 included studies gave clear descriptions of sample de-
mographics, inclusion/exclusion criteria and sample size.
Moreover, although there was disparity in the range of sample
sizes (25–21,077), there was a pooled sample of 43,984 stroke
survivors. These samples were derived from four countries
across three continents. In light of this, it can be assumed, with
a certain level of confidence, that the reviews findings are
generalizable to stroke survivors from developed, western
cultures.
There were no defined cutoffs for quality assessment
scores. Nevertheless, assessment of the individual items, for
each paper, was important to identify gaps in research quality.
Only two papers reported a sample size calculation. This is
problematic when meta-analysis is not possible, as the finding
that some determinants tested did not significantly influence
adherence may be due to small sample sizes and underpow-
ered studies, rather than genuine lack of relationships.
Moreover, three studies did not make the original question-
naire available or provide sufficient information on measure-
ment of determinants [13, 43, 44]. As several studies used
tailor-made questionnaires, including a mix of non-validated
and validated scales, it would be helpful to future systematic
reviewers to make the full questionnaires available.
Additionally, there were only seven discrete samples of
participants across the 12 papers. Two papers [43, 44] reported
on the same sample, followed up at different time points. Five
papers [36–38, 45, 46] used the same sample of trial partici-
pants’ baseline data, with each paper testing different combi-
nations of determinants that might influence medication ad-
herence. We have therefore presented not only the number of
determinants tested that were found to be significant but also
the proportion of samples in which a type of determinant was
both tested and found to be a significant predictor. Given the
relatively small number of independent samples included in
this review, and the partial coverage of the TDF domains in
the included studies, there remains a need for further, well-
designed studies of the predictors of medication adherence in
stroke survivors.
The secondary aim of this review, to establish the magni-
tude of the relationships between determinants and behaviour,
could not be achieved, as study design choices were too het-
erogeneous to permit meta-analysis. Measurement of medica-
tion adherence was inconsistent across included papers, with
different self-report or objective measures chosen, assessing
adherence at a number of different time points. This has been
identified as an issue in previous research attempting to syn-
thesise data regarding medication adherence [e.g. 19]. All
methods of adherence measurement have limitations.
Electronic, objective monitoring may be the best currently
available option, but nevertheless can be reactive and is costly.
Prescription data provides information about medication
possession, but not whether medication was taken, while
self-report measures are subject to recall and social desirability
biases. The majority of studies in the review used self-report
measures. Future research might usefully further explore psy-
chological and other predictors of adherence to stroke second-
ary preventive medication using objective adherence
measurement.
It could be suggested that the varying methods of medica-
tion adherence measurement add strength to the findings in
this review. For example, the determinant concerns about
medications was measured across five studies (3/7 samples)
[13, 37, 42, 45, 46], with a significant relationship identified
between this determinant and medication adherence. Across
the five studies, medication adherence was measured by three
different self-report and one pill count method. Irrespective of
the measurement method, a significant relationship was
found, thus strengthening the conclusion that there is a rela-
tionship between determinant and behaviour.
Limitations
The number of papers that met final inclusion criteria was
small. Authors were contacted (N = 19) to request more infor-
mation or manuscripts relating to data that had previously
been presented at conferences or where no full text access
could be found, but only seven responded. Other systematic
reviewers have reported a similar issue [52].
In spite of the rigorousmethod applied to determinant map-
ping, there is still an element of subjectivity in the process.
The task relies on interpretation of TDF domain definitions
and descriptions of scales provided in the primary studies.
No determinants were mapped into six TDF domains.
However, other research has highlighted the importance of
some of these domains in sustained behaviour change. For
example, Nicholson and colleagues (2014) identified the im-
portance of ‘Environmental context and resources’ with the
engagement of physical activity in stroke survivors [53]. The
limited breadth of domains tested through this review may
represent a ‘file drawer’ problem or limitations in the study
designs. This may also be in part due to the inclusion of only
psychological determinants, which could be less likely to map
into some TDF domains. In particular, the search strategy
would have retrieved studies that assessed the association of
stroke survivors’ perceptions of their environmental context
and resources with adherence, but not studies simply testing
whether the presence or absence of different environmental
and contextual features influenced adherence. Factors such
as prescription costs and health insurance coverage also need
to be considered. However, non-adherence remains an issue
even in healthcare systems providing universal healthcare
coverage and prescriptions free of charge (e.g. 13).
Therefore, understanding psychological determinants of ad-
herence remains an important issue to inform intervention
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design. Despite efforts in the search strategy to access a variety
of literature, the 12 selected papers were all identified from the
peer-reviewed literature; none were found in the ‘grey’ litera-
ture, which could result in publication bias. Future work
should aim to measure a broader range of psychological de-
terminants that influence medication adherence in stroke sur-
vivors to enhance a more holistic understanding of this
behaviour.
Conclusions
The findings from this review have identified psychological
determinants, amenable to change, that influence medication
adherence in stroke survivors. ‘Beliefs about Consequences’,
‘Knowledge’ and ‘Emotions’ were the most influential do-
mains. As the TDF underpins the Behaviour Change Wheel,
a framework for intervention development, future work can
systematically identify the intervention functions and BCTs
that target the determinants within each domain. In doing so,
there is a greater chance that medication adherence will be
enhanced as the intervention will be grounded in both a theo-
retical understanding of the behaviour and will be applying
evidence into practice. Future research should strive for clarity
and transparency to support pooling of data, most specifically
focused on consistency ofmedication adherence measurement
and testing of a broad range of determinants using
standardised measures.
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